MAGIC TRIAL in gastric cancer
Reading Document
Medical Text Search
MAGIC trial perioperative chemotherapy gastric cancer ECF
Medical Text Search
gastric cancer perioperative chemotherapy survival outcomes resection
GradeResponse
GradeResponse
MAGIC Trial — Perioperative Chemotherapy in Gastric Cancer
Background
The MAGIC trial (Medical Research Council Adjuvant Gastric Infusional Chemotherapy) was a landmark randomized controlled trial published by Cunningham et al. in the NEJM (2006) that established perioperative chemotherapy as a standard of care for resectable gastric cancer in the West.
Study Design
| Feature | Detail |
|---|---|
| Trial type | Phase III RCT |
| Population | Resectable gastric or lower esophageal adenocarcinoma (stage II–III) |
| Arms | Perioperative ECF chemotherapy + surgery vs. surgery alone |
| n | 503 patients |
| Setting | UK multicenter |
Chemotherapy Regimen — ECF
3 cycles pre-op + 3 cycles post-op:
- Epipodophyllotoxin → Epicirubicin 50 mg/m² IV day 1
- Cisplatin 60 mg/m² IV day 1
- Fluorouracil (5-FU) 200 mg/m²/day continuous IV infusion, days 1–21
Each cycle = 21 days; 3 pre-operative cycles, then surgery, then 3 post-operative cycles (if tolerated).
Key Results
| Endpoint | Surgery Alone | Perioperative ECF + Surgery | Significance |
|---|---|---|---|
| 5-year overall survival | 23% | 36% | HR 0.75, p = 0.009 |
| Progression-free survival | Shorter | Significantly longer | HR 0.66 |
| Curative resection rate (R0) | 69% | 79% | Favored chemo arm |
| Tumor downstaging | — | Significant (smaller, less nodal involvement) | — |
The survival benefit translated to a 13% absolute improvement in 5-year OS and a 25% relative reduction in the risk of death.
Pathologic Findings
Perioperative chemotherapy led to significant tumor downstaging:
- Smaller tumor size
- Fewer positive lymph nodes
- Higher proportion of T1/T2 tumors in the chemotherapy arm vs. T3/T4 in the surgery-alone arm
Tolerability & Completion
- Only about ~42% of patients who started pre-operative chemotherapy actually completed all 3 post-operative cycles, highlighting a significant challenge in the perioperative approach
- The most common toxicities were nausea, neutropenia, and fatigue
Significance & Impact
- Established perioperative chemotherapy as a standard of care for medically fit patients with cTNM stage II–III resectable gastric cancers (Harrison's, p. 2455)
- Demonstrated that neoadjuvant chemotherapy can downstage tumors, increasing R0 resection rates
- Prompted subsequent trials (FLOT4, FNCLCC/FFCD) that further refined the perioperative approach
- The FLOT4 trial later superseded ECF with FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), showing superior OS (50% vs. 45% 3-year OS), making FLOT the current preferred regimen in Western practice
Current Practice (Post-MAGIC)
| Approach | Regimen | Evidence |
|---|---|---|
| Preferred perioperative | FLOT × 4 pre-op + 4 post-op | FLOT4 trial (Al-Batran, NEJM 2019) |
| Alternative | ECF/EOF/ECX/EOX | MAGIC trial |
| Adjuvant chemoradiation | 5-FU + RT (MacDonald) | INT-0116 (US, post-op) |
| Adjuvant chemo (Asia) | S-1 or capecitabine + oxaliplatin | ACTS-GC, CLASSIC trials |
Bottom line: The MAGIC trial was the first major RCT to demonstrate that wrapping surgery with systemic chemotherapy (ECF) significantly improves survival in resectable gastric cancer, shifting the paradigm from surgery-first to a multimodality approach. It remains a foundational reference even though FLOT has now become the preferred regimen.
This is a shared conversation. Sign in to Orris to start your own chat.